Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

63234 1503498110HCLSReviewIndonesiaAugust2017.pdf
Energy Boardroom

Irreconcilable differences? Allergan investors wary of suitor Valeant's cost-slashing style

28.04.2014 / Fierce Pharma

Last week, Valeant CEO J. Michael Pearson seemed confident he could woo Allergan shareholders with his $46 billion bid–even after the California-based company's board swallowed a poison pill. But now, some of Allergan's largest shareholders are begging to differ. And that could threaten Pearson's quest to bag his latest target.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: